baltimore conference logo
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Clinical Cases in Relapsed and Refractory DLBCL

EP1: Case 1: Relapsed DLBCL, Transplant Eligible

October 28th 2020

EP2: Case 1: Waiting for FISH Results in DLBCL

October 28th 2020

EP3: Case 1: Identifying Patients for CNS Prophylaxis in DLBCL

October 28th 2020

EP4: Case 1: Outcomes in Chemotherapy-Treated Patients With DLBCL

October 28th 2020

EP5: Case 1: Therapy for Relapsed DLBCL in Transplant-Eligible Patients

October 28th 2020

EP6: Case 1: Trials in CAR T-Cell for Patients With Relapsed/Refractory DLBCL

October 28th 2020

EP7: Case 1: Therapeutic Options After CAR T-Cell in Relapsed/Refractory DLBCL

October 28th 2020

EP8: Case 2: R-CHOP Refractory DLBCL, Transplant Ineligible

October 28th 2020

EP9: Case 2: Therapeutic Options in Patients With Transplant-Ineligible, Treatment-Refractory DLBCL

October 28th 2020

EP10: Case 2: Considerations for Choosing a Second-Line Therapy for DLBCL

October 28th 2020